Inclusion Criteria:  Patients eligible for the trial must comply with all of the following:  Currently diagnosed or receiving treatment for a widespread chronic pain condition, including but not limited to:  Axial pain of any origin Polyathralgia of any origin Myofascial pain of any origin A diagnosis of chronic widespread pain or FM Able to provide informed written consent ≥18 years Able to commit time to the trial treatment schedule of 6 weeks Score as low or moderate risk on the COVID-19 risk stratification tool - applicable for the duration of the pandemic  Exclusion Criteria:  Pregnancy Severe skin diseases (e.g. skin cancer, severe eczema, dermatitis, or psoriasis) Body weight ≥136kg, as per manufacturer instructions [see Appendix 3] Uncontrolled co-morbidities (e.g. uncontrolled diabetes defined as HbA1c >69mmol/mol, decompensated heart failure, major psychiatric disturbance such as acute psychosis or suicidal ideation) Use of systemic corticosteroid therapy including oral prednisolone or corticosteroid injections within the preceding 6 months as recommended by the manufacturer; steroids are thought to inhibit the anti-inflammatory effect of photobiomodulation therapy Known active malignancy Inability to enter the NovoTHOR device or lie flat for 20 minutes (either due to physical reasons or other e.g. claustrophobia) Patients speaking a language for which an interpreter cannot be sought